Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT

Lawhn-Heath, Courtney; Flavell, Robert R.; Glastonbury, Christine M.; Hope, Thomas A.; Behr, Spencer C.

doi:10.1097/rlu.0000000000001569

Cited by 25 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although other tumors of the head and neck, such as adenoid cystic carcinoma, squamous cell carcinoma, or medullary thyroid cancer, may also be PSMA-positive ( 7 – 9 ), in our patient, a right-sided accessory parotid gland was highly probable owing to corresponding magnetic resonance imaging findings and PSMA uptake intensity. An accessory parotid gland is defined as a separated salivary gland anterior to the proper parotid gland and appears in 10% of humans ( 10 ).…”

Section: Discussionmentioning

confidence: 59%

Dedicated Verification of an Accessory Parotid Gland via Minimal-Activity PSMA-PET/CT

et al. 2020

View full text Add to dashboard Cite

Gallium-68-labeled prostate-specific membrane antigen ligands are not only established radiopharmaceuticals for staging of prostate cancer but also accumulate physiologically in nonprostate organs, including the salivary glands. We show the converted application of prostate-specific membrane antigen -positron emission tomography/computed tomography (PSMA-PET/CT) as a dedicated method to depict salivary gland tissue using a region-focused, low-dose protocol. An accessory parotid gland at the right buccal region could be confirmed; therefore, further diagnostic or invasive therapeutic steps were not necessary.

show abstract

Section: Discussionmentioning

confidence: 59%

Dedicated Verification of an Accessory Parotid Gland via Minimal-Activity PSMA-PET/CT

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Indeed, expression of PSMA is not specific to prostate tissue and PCa, as it might be increasingly expressed in the process of neovascularization of numerous solid tumors such as renal cell cancer [ 64 ], hepatocellular carcinoma, and squamous cell carcinoma of head and neck [ 65 ] (see Figure 4 ). In a prospective pilot study by Kessler et al including 37 suspected malignant hepatic lesions of seven patients, results revealed that more than 95% hepatocellular carcinoma lesions expressed PSMA [ 66 ].…”

Section: Pitfalls and Limitation Of Psma Pet Examinationmentioning

confidence: 99%

Clinical Applications of PSMA PET Examination in Patients with Prostate Cancer

Rasul

Haug

2022

Cancers

View full text Add to dashboard Cite

With the progressive aging of the population in industrially developed countries, as well as advances in diagnostic and biopsy techniques and improvements in patient awareness, the incidence of prostate cancer (PCa) is continuously increasing worldwide. Therefore, PCa is currently considered as the second leading cause of tumor-related death. Early detection of the tumor and its metastasis is essential, as the rate of disease recurrence is high and occurs in 27% to 53% of all patients who underwent curative therapy with radical prostatectomy or local radiotherapy. In this regard, the prostate specific membrane antigens, abbreviated as PSMAs, are type II membrane proteins that are highly expressed on the surface of malignant prostate tissue in PCa, particularly in aggressive, androgen-deprived, metastatic, and hormone-refractory PCa, and they are inversely associated with the androgen level. Up to 95% of adenocarcinomas of the prostate express PSMA receptors on their surface. Today, radionuclides that bind to these PSMA peptides are widely accepted for diagnostic and therapeutic purposes to specifically image and target prostate tumor cells at the molecular level, a process referred to as targeted theranostics. Numerous studies have demonstrated that the integration of these peptides into diagnostic and therapeutic procedures plays a critical role in the primary staging and treatment decisions of especially high-risk PCa, expands therapeutic options for patients with advanced stage of prostate tumor, and prolongs patients’ survival rate. In this review article, we intend to briefly spotlight the latest clinical utilization of the PSMA-targeted radioligand PET imaging modality in patients with different stages of PCa. Furthermore, limitations and pitfalls of this diagnostic technique are presented.

show abstract

“…Benign pathologic states may also mimic PCa, such as fibrous dysplasia, healing bone fractures, or granulomatous diseases (e.g., sarcoidosis) (25,(32)(33)(34). Nonprostatic malignancies that may demonstrate uptake of PSMAtargeted radiotracers include, but are not limited to, pancreatic NEN, squamous cell carcinoma of the oropharynx, hepatocellular carcinoma, and renal cell carcinoma (25,(35)(36)(37)(38). Although the detection rate and recognition of potentially confusing false-positive or false-negative findings on PSMA-targeted PET scans can almost certainly be increased by appropriate training, the way in which PSMA-RADS may live up to its full potential is in providing readers with a mechanism to formalize uncertainty about such findings and to recommend any further workup to clinicians.…”

Section: Potential Applicationsmentioning

confidence: 99%

Novel Structured Reporting Systems for Theranostic Radiotracers

Werner

Bundschuh²,

Bundschuh³

et al. 2019

J Nucl Med

View full text Add to dashboard Cite

Standardized reporting is more and more routinely implemented in clinical practice, and such structured reports have a major impact on a large variety of medical fields, such as laboratory medicine, pathology, and, recently, radiology. Notably, the field of nuclear medicine is constantly evolving as novel radiotracers for numerous clinical applications are developed. Thus, framework systems for standardized reporting in this field may increase clinical acceptance of new radiotracers, allow for inter-and intracenter comparisons for quality assurance, and be used in global multicenter studies to ensure comparable results and enable efficient data abstraction. In the last couple of years, several standardized framework systems for PET radiotracers with potential theranostic applications have been proposed. These include systems for prostate-specific membrane antigen-targeted PET agents to diagnose and treat prostate cancer, and systems for somatostatin receptor-targeted PET agents to diagnose and treat neuroendocrine neoplasia. In the present review, the framework systems for these 2 types of cancer will be briefly introduced, followed by an overview of their advantages and limitations. In addition, potential applications will be defined, approaches to validate such concepts will be proposed, and future perspectives will be discussed.

show abstract

Incidental Detection of Head and Neck Squamous Cell Carcinoma on 68Ga-PSMA-11 PET/CT

Cited by 25 publications

References 19 publications

Dedicated Verification of an Accessory Parotid Gland via Minimal-Activity PSMA-PET/CT

Dedicated Verification of an Accessory Parotid Gland via Minimal-Activity PSMA-PET/CT

Clinical Applications of PSMA PET Examination in Patients with Prostate Cancer

Novel Structured Reporting Systems for Theranostic Radiotracers

Contact Info

Product

Resources

About